SarcopeniaSTaRNCT06585865
Strength Training and Resveratrol
A study testing Resistance training and Resveratrol 500 mg oral once daily. in people with Sarcopenia and Anabolic Resistance, run by Texas Tech University at 1 site in United States.
Trial summary
The main goal of this study is to find out if supplementing with resveratrol improves skeletal muscle adaptations to strengthening exercise (resistance training or strength training) in adults age 60+, and to determine whether circulating vehicles of inter-organ communication (extracellular vesicles) and their cargo… Read more about this study
- Who is it for?
- Ages 60 years and olderHealthy volunteers can take part
- Conditions the study is for
- Sarcopenia, Anabolic Resistance
- What is being tested?
- Resistance training and Resveratrol 500 mg oral once daily.
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Jun 2025to Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 60+
- Minimally active (less than 1 hour of structured exercise/week other than walking)
- No resistance training for the previous 6 months
- Not currently taking resveratrol supplements
- Stable medication, supplement, dietary, and physical activity regimens for the previous 3 months and no plans to change throughout the study period
- Body mass at least 110 lbs
Who cannot join
- Medical complications that could increase risk during exercise (e.g., cardiovascular disease, uncontrolled hypertension, type 1 or 2 diabetes, orthopedic contraindication to exercise, kidney disease, etc.)
- Cannabis or nicotine use
- Consume more than 7 alcohol-containing beverages per week
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Department of Kinesiology & Sport Management, Texas Tech University
Lubbock, Texas, 79409
Danielle E Levitt, PhD, 806-834-1830, danielle.levitt@ttu.edu
About this study
Official title: Resveratrol-mediated Changes in Extracellular Vesicle microRNA Cargo as a Novel Contributor to Resistance Training-induced Skeletal Muscle Adaptations in Older Adults
The main goal of this study is to find out if supplementing with resveratrol improves skeletal muscle adaptations to strengthening exercise (resistance training or strength training) in adults age 60+, and to determine whether circulating vehicles of inter-organ communication (extracellular vesicles) and their cargo might help explain those responses. The investigators will also examine whether resveratrol supplementation improves blood vessel function and cognitive function (brain health) in response to strength training.
Read the detailed description
After screening and providing informed consent, participants (healthy older adults, age 60+, minimally active) will be familiarized with the procedures and undergo pre-testing. After pre-testing, participants will be assigned to supplement with resveratrol or placebo (double-blinded) daily while undergoing a strength training intervention. Strength training will be performed 3x/week for two 6-week blocks, and each visit will be supervised by a member of the study team. An additional week of testing will follow each of the two 6-week blocks.
- Conditions
- Sarcopenia, Anabolic Resistance
- Being tested
- Resistance training, Resveratrol 500 mg oral once daily., Placebo
- Keywords
- Resistance training, Aging, Resveratrol, Sarcopenia, Extracellular Vesicles, MicroRNAs
- Medical subject headings
- Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resistance trainingBehavioural
Also called Strength training
After pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block.
Resveratrol 500 mg oral once daily.Dietary supplement
Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
PlaceboDietary supplement
Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
| Study group | Role | What they receive |
|---|---|---|
| Resveratrol (RSV) group | Experimental | Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored. Receives: Behavioral: Resistance training; Dietary Supplement: Resveratrol 500 mg oral once daily. |
| Placebo | Placebo comparator | Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored. Receives: Behavioral: Resistance training; Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Circulating extracellular vesicle microRNA profile
Circulating extracellular vesicles will be isolated from plasma and their microRNA cargo will be sequenced.
Measured: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Muscle torque
Participants will be instructed to try and straighten their leg, against resistance, as forcefully as possible and maximal torque of the quadriceps assessed using a dynamometer.
Measured: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Muscle fatigability
Participants will perform 32 repetitions of knee extensions on a dynamometer and the change in torque from the beginning to the end will be used to indicate fatigability.
Measured: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Muscle strength
Participants will perform submaximal testing to assess strength on key exercises included in the strength training protocol.
Measured: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Appendicular skeletal muscle mass index
Assessed using dual-energy x-ray absorptiometry (DEXA)
Measured: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Secondary outcomes (6)
Waist-to-hip ratio
Waist and hip circumferences measured using measuring tape
Measured: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Vascular function
Flow-mediated dilation
Measured: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Cognitive function
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Measured: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Grip strength
Handgrip dynamometry
Measured: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Lower body strength/endurance
Chair stand test (30 seconds)
Measured: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Gait speed
4-m walk test
Measured: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start13 Jun 2025
- Primary completionJul 2027 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- After pre-testing, participants will be randomized to supplement with resveratrol (500 mg) or placebo for 14 weeks. All participants will complete two 6-week blocks of supervised strength training (full body, 3 days/week); each block will be followed by one week of testing.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Texas Tech University
- Sponsor type
- University, hospital or other
- Collaborators
- National Strength and Conditioning Association
- Responsible party
- Sponsor
- Investigators
- Danielle E Levitt, PhD, Principal investigator, Texas Tech University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06585865
- Sponsor's protocol ID
- YI-2024-02
- Other IDs
- IRB 2024-587
- Acronym
- STaR
- Status last verified
- Jul 2026
- First submitted
- 3 Sep 2024
- Last updated
- 7 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified data from human participants (other than large-scale data) will be deposited into the TTU Dataverse with restricted access - by request only. Data will be linked only with a unique code. MicroRNA sequencing data will be deposited to the Gene Expression Omnibus (GEO). The following will be submitted to accompany data: * Full study protocol * Names and descriptions of data sets * Annotated data collection forms * Data dictionary * Documentation of calculated variables * Any changes made to the protocol over time * Frozen datasets used for the primary publication, when applicable
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Resveratrol-mediated Changes in Extracellular Vesicle microRNA Cargo as a Novel Contributor to Resistance Training-induced Skeletal Muscle Adaptations in Older Adults
- ClinicalTrials.gov ID
- NCT06585865
- Acronym / sponsor ID
- STaR / YI-2024-02
- Conditions
- Sarcopenia, Anabolic Resistance
- Keywords
- Resistance training, Aging, Resveratrol, Sarcopenia, Extracellular Vesicles, MicroRNAs
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Texas Tech UniversityUniversity, hospital or other
- Collaborators
- National Strength and Conditioning Association
- Study start
- 13 Jun 2025 (actual)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main goal of this study is to find out if supplementing with resveratrol improves skeletal muscle adaptations to strengthening exercise (resistance training or strength training) in adults age 60+, and to determine whether circulating vehicles of inter-organ communication (extracellular vesicles) and their cargo might help explain those responses. The investigators will also examine whether resveratrol supplementation improves blood vessel function and cognitive function (brain health) in response to strength training.
Detailed description
After screening and providing informed consent, participants (healthy older adults, age 60+, minimally active) will be familiarized with the procedures and undergo pre-testing. After pre-testing, participants will be assigned to supplement with resveratrol or placebo (double-blinded) daily while undergoing a strength training intervention. Strength training will be performed 3x/week for two 6-week blocks, and each visit will be supervised by a member of the study team. An additional week of testing will follow each of the two 6-week blocks.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- After pre-testing, participants will be randomized to supplement with resveratrol (500 mg) or placebo for 14 weeks. All participants will complete two 6-week blocks of supervised strength training (full body, 3 days/week); each block will be followed by one week of testing.
| Arm | Type | Receives |
|---|---|---|
| Resveratrol (RSV) group | Experimental | Behavioral: Resistance training, Dietary Supplement: Resveratrol 500 mg oral once daily.Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored. |
| Placebo | Placebo comparator | Behavioral: Resistance training, Dietary Supplement: PlaceboParticipants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored. |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age 60+
- Minimally active (less than 1 hour of structured exercise/week other than walking)
- No resistance training for the previous 6 months
- Not currently taking resveratrol supplements
- Stable medication, supplement, dietary, and physical activity regimens for the previous 3 months and no plans to change throughout the study period
Key exclusion criteria (3 listed)
- Medical complications that could increase risk during exercise (e.g., cardiovascular disease, uncontrolled hypertension, type 1 or 2 diabetes, orthopedic contraindication to exercise, kidney disease, etc.)
- Cannabis or nicotine use
- Consume more than 7 alcohol-containing beverages per week
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resistance trainingAlso: Strength trainingAfter pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block. | Behavioural | Placebo, Resveratrol (RSV) group |
| Resveratrol 500 mg oral once daily.Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored. | Dietary supplement | Resveratrol (RSV) group |
| PlaceboParticipants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored. | Dietary supplement | Placebo |
Primary outcome
Circulating extracellular vesicle microRNA profile
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Circulating extracellular vesicles will be isolated from plasma and their microRNA cargo will be sequenced.
Muscle torque
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Participants will be instructed to try and straighten their leg, against resistance, as forcefully as possible and maximal torque of the quadriceps assessed using a dynamometer.
Muscle fatigability
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Participants will perform 32 repetitions of knee extensions on a dynamometer and the change in torque from the beginning to the end will be used to indicate fatigability.
Muscle strength
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Participants will perform submaximal testing to assess strength on key exercises included in the strength training protocol.
Appendicular skeletal muscle mass index
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Assessed using dual-energy x-ray absorptiometry (DEXA)
6 secondary outcomes
Waist-to-hip ratio
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Vascular function
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Cognitive function
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Grip strength
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Lower body strength/endurance
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Gait speed
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
- Individual participant dataSharing planned: Yes. De-identified data from human participants (other than large-scale data) will be deposited into the TTU Dataverse with restricted access - by request only. Data will be linked only with a unique code. MicroRNA sequencing data will be deposited to the Gene Expression Omnibus (GEO). The following will be submitted to accompany data: * Full study protocol * Names and descriptions of data sets * Annotated data collection forms * Data dictionary * Documentation of calculated variables * Any changes made to the protocol over time * Frozen datasets used for the primary publication, when applicable
Related trials for Sarcopenia
Not yet recruiting
Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based Exercise for Sarcopenia in Huntington's Disease
Huntington Disease, Sarcopenia
Enrolling by invitation
Physical Activity Interventions for Sleep Improvement and Sedative-Hypnotic Reduction in Middle-Aged and Older Adults: Investigating the Role of Sarcopenia
Insomnia Chronic, Hypnotics and Sedatives
Recruiting
Resistance vs Aerobic Prehabilitation Before Colorectal Cancer Surgery
Colorectal Cancer, Colorectal Neoplasms
Active, not recruitingObservational study
Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's Syndrome
Primary Sjögren Syndrome, Sarcopenia
Not yet recruiting
PROfiles of FGF-19 Post-prandial Secretion in Older Adults With Frailty and Without Frailty
Frailty, Sarcopenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Danielle E Levitt, PhD principal investigator
Texas Tech University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Resistance training and Resveratrol 500 mg oral once daily. in people with Sarcopenia and Anabolic Resistance, run by Texas Tech University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Danielle E Levitt, PhD (806-834-1830, danielle.levitt@ttu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Circulating extracellular vesicle microRNA profile (time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.